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Abstract
Background and objectives Primary pharmacological
therapy may be the only viable treatment option for many
patients with acromegaly, especially those presenting with
advanced disease with large inoperable tumors. Long-act-
ing somatostatin analogs are currently the first-line treat-
ment of choice in this setting, where they provide
biochemical control and reduce tumor size in a significant
proportion of patients. We herein present a brief overview
of the role of primary pharmacological therapy in the
treatment of acromegaly within the context of Latin
America and support this with a representative case study.
Case description A 20 year old male presented with
clinical and biochemical evidence of acromegaly. The
glucose-suppressed growth hormone (GH) was 5.3 lg/L,
his insulin-like growth factor-1(IGF-1) was 3.5 times the
ULN and serum prolactin greater than 4,000 lg/L. Pituitary
MRI revealed a large and invasive mass, extending supe-
riorly into the optic chiasm and laterally into the left cav-
ernous sinus. He was treated with a combination of
octreotide and cabergoline with remarkable clinical
improvement, normalization of GH and IGF-1 values and
striking shrinkage of the adenoma.
Conclusion This case illustrates how effective the pharma-
cological therapy of acromegaly can be and yet at the same
time, raises several important issues such as the need for life-
long treatment with costly medications such as the somato-
statin analogs. Access to these agents may be limited in regions
where resources are restricted and clinicians face challenges in
order to make the most efficient use of available options.
Keywords Acromegaly  Pituitary  Latin America 
GH  IGF-1  Somatostatin analogs  Dopamine
agonists  Pegvisomant
Introduction
Acromegaly is characterized by excessive secretion of
growth hormone (GH), usually due to a pituitary tumor,
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and a subsequent increase in insulin-like growth factor-1
(IGF-1) release from the liver and other tissues [1]. Long-
term exposure to elevated levels of these two hormones
underlies many of the debilitating clinical features of
acromegaly, such as arthropathy, cardiomyopathy, diabetes
mellitus and sleep apnea [1]. Pharmacological intervention
in acromegaly is therefore aimed primarily at suppressing
secretion of GH from the pituitary or blocking the actions
of GH at it receptors, along with a secondary reduction in
circulating IGF-1 levels [1, 2].
There are three classes of pharmacological therapy used
routinely to control disease activity in acromegaly: dopa-
mine agonists (principally cabergoline) and somatostatin
analogs (SSAs), which suppress the secretion of GH, and a
GH receptor antagonist (pegvisomant) [2]. However, access
to these different classes of drugs may vary at the local level,
both between and within individual countries, and this is
particularly applicable to Latin America [3]. Although
pharmacological therapy is used predominantly as second-
ary therapy for persistent or recurrent acromegaly following
non curative surgery, it is increasingly being used as primary
therapy in the following situations: (1) patients in whom
surgery is not an initial option due to tumor location and
limited chance of surgical cure, (2) as short-term therapy
before surgery aimed at reducing perioperative anesthetic
morbidity, or (3) due to patient preference [2, 4, 5]. Primary
pharmacological therapy may also be appropriate if there are
clinical contraindications to surgery or experienced pituitary
neurosurgeons are not available. The current article provides
a brief overview of the role of primary pharmacological
therapy in the treatment of acromegaly in the context of Latin
America and supports this with a representative case study.
Current recommendations for primary pharmacological
therapy
Surgical resection–usually, transsphenoidal microscopic or
endoscopic surgery (TSS)–is recommended as the primary
treatment of choice in patients with microadenomas or
intrasellar macroadenmas, provided an experienced pitui-
tary neurosurgeon is available to perform the procedure [3–
6]. In these situations, surgery can lead to durable clinical,
biochemical and tumor volume control of the patient [7]. In
addition, TSS is indicated in patients with invasive mac-
roadenoma associated with considerable mass effects such
as rapidly progressing optic chiasm compression [4, 7].
Pharmacological therapy is generally used as adjuvant
treatment in the setting of persistent disease despite sur-
gical intervention [4, 8].
A role for primary pharmacological therapy, especially
with SSAs, has been suggested in patients with macroad-
enomas with stable local mass effects who have a minimal
chance of surgical cure (because of extrasellar extension of
the tumor, especially into the cavernous sinus) or in
patients who are poor surgical candidates or who express a
preference for pharmacological treatment [3, 4, 6]. In
patients with macroadenomas that are not likely to be cured
with surgical intervention, debulking surgery may be rec-
ommended to improve the response to subsequent phar-
macological therapy [4]. Radiotherapy is usually reserved
as a third-line option for patients with recurrent or persis-
tent disease activity after unsuccessful surgery, and who
are resistant or intolerant to pharmacological treatment [8].
Options for primary pharmacological therapy
Currently, long-acting SSAs are generally considered the
first choice for the pharmacological treatment of acromegaly
[2, 9, 10]. Long-acting formulations are more widely used
due to increased compliance and patient convenience [2]. In
approximately 50 % of cases where SSA primary therapy is
used in clinical practice, the indication is the presence of a
macroadenoma with lateral extension with or without cav-
ernous sinus invasion, with the remainder of cases being for
macroadenoma without compressive symptoms, for elderly
patients, or based on patient preference [10]. The FDA
approved subcutaneous octreotide in 1988, shortly after it
was launched in Europe; it became available in Latin
America in the early 1990s. Octreotide LAR was introduced
in Europe in 1997 and was eventually approved by most
Latin American Countries between 2000 and 2003. The most
commonly used 20 mg formulation has an approximate
monthly cost that ranges from $1000 USD for government
institutions that usually purchase large amounts of the
medication, to up to $2000 USD for the individual private
patient. Lanreotide autogel became available in several Latin
American Countries as of 2008. The government price for
the 90 and 120 mg formulations is approximately $900 and
$1200 USD, respectively. Lanreotide autogel’s relatively
easy administration can result in significant indirect cost
savings, since the patient does not need to come monthly to a
specialized facility in order to get his/her injection.
A meta-analysis of prospective clinical trials up to the year
2003, suggests that long-acting SSAs reduce GH levels to
\2.5 lg/L in just over 50 % of patients and normalize IGF-1
levels in a similar proportion [2, 11]. However, it should be
noted that these figures are derived mainly from studies with a
pre-selection bias since, for the most part, they involved
Caucasian patients previously responding to non-depot for-
mulations of SSAs. As expected, response rates are lower
among non-preselected patients [2]. In a more recent multi-
national study looking at SSAs solely in unselected treatment-
naı¨ve patients, including participants from Latin America, a
GH level B 2.5 lg/L was achieved in 43–44 % and a normal
age-adjusted IGF-1 in 34–38 % of patients (after 24 or
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48 weeks) and both goals were achieved in 25–27 % [12].
Other longer-term studies in European, treatment-naı¨ve pop-
ulations have reported higher response rates for both GH
(69–100 %) and IGF-1 (70–98 %), but these are likely to have
been influenced by pre-selection bias and the use of per pro-
tocol rather than intention-to-treat analyses [13, 14]. To date,
several predictors of biochemical response to SSAs have been
identified, including gender, age, initial GH and IGF-I levels,
and tumor mass, as well as adequate expression of somato-
statin receptor types 2 and 5 [15, 16].
The SSAs are also effective at improving clinical symp-
toms of acromegaly, such as headache, fatigue, perspiration,
and joint pain [12, 17], and have been shown to reduce the
prevalence and severity of several measures of cardiomyop-
athy (arrhythmias, left ventricular hypertrophy, diastolic
dysfunction and systolic dysfunction) and to improve certain
cardiovascular risk factors, including hypertension and
hypertriglyceridemia [14, 18, 19]. Interestingly, improve-
ments in systolic function appear to be greatest when SSAs are
used as primary therapy rather than after surgery, and it has
been suggested that this may relate to a direct effect on the
heart and/or better preservation of anterior pituitary function
[18, 19]. Furthermore, SSAs induce clinically significant
tumor shrinkage in close to 70 % of primarily treated patients,
and some evidence suggests that this rate is increased when
using this analogs for long periods of time [12, 14, 20–22].
Dose optimization with SSAs has been shown to be an
effective means to improve treatment outcomes in patients
with acromegaly who have inadequate response to the starting
dose or who fail to achieve complete control of their disease
[12, 23, 24].
Dopamine agonists (principally cabergoline) may also be
used as primary pharmacological therapy [4, 10, 25]. Ca-
bergoline has the advantage of oral administration and lower
cost and may be the only available option if local resources are
limited [25, 26]. In a meta-analysis of 9 studies from the lit-
erature, cabergoline alone was able to normalize IGF1 in 34 %
of patients [26]. The evidence does not support the commonly
held view that dopamine agonists, which also suppress the
secretion of prolactin, are more effective in patients with
hyperprolactinemia (who may harbor mixed GH- and pro-
lactin-secreting pituitary tumors) [25, 26]. Combination
therapy with SSAs and dopamine agonists may be appropriate
in cases of partial response to monotherapy [4, 26].
Pharmacological therapy with the GH antagonist peg-
visomant is generally restricted to patients with inadequate
response or tolerability to SSAs [4]. Although initial
studies reported a close to 100 % IGF-1 normalization rate,
long-term studies reveal that this figure is between 60 and
70 % [27–29]. The addition of pegvisomant 10–30 mg/day
is another option that has proven to be effective in patients
resistant to monthly injections of SSAs [30]. Weekly and
twice-weekly dosing (median dose 60 mg/week) has also
been shown to be effective and could reduce costs versus
the currently approved daily dosing regimen [31–33].
Pegvisomant is used, albeit as a tertiary option, in some
(Venezuela, Argentina, Brazil) but not all Latin American
Countries (Mexico, Chile, Colombia, Peru, Uruguay). Even
at the lowest possible dose, the economic burden that
represents the long-term treatment with pegvisomant can
be overwhelming; the cost per month for a patient con-
trolled on 10 mg a day is between $7000 and $9000 USD.
Fig. 1 Gadolinium-enhanced, T1-weighted MRI scans (coronal view) of pituitary tumor at diagnosis (left) and after 6 months of treatment with
an SSA and dopamine agonist
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The combination treatment approach
Rather than waiting for surgical approaches to fail before
considering pharmacological therapy, another approach is
the upfront consideration of pharmacological and surgical
approaches together. Treatment with SSAs before TSS has
been shown to improve surgical cure rates in patients with
acromegaly [33–38]. However, not all studies have shown
a benefit [39–42], and the case for pre-surgical treatment
with SSAs continues to be debated [43, 44]. Similarly, as
noted above, surgical debulking (in patients not initially
amenable to complete surgical resection) has also been
shown to improve the likelihood of biochemical control by
SSAs [45–49].
Such combination approaches may be particularly
appropriate for patients with advanced disease who may not
be immediate candidates for surgery [4]. In addition to
reducing tumor size and improving the chances of successful
surgical resection, pre-surgical treatment with SSAs, by
virtue of improving soft tissue swelling and achieving con-
trol of co-morbidities (such as hypertension, cardiomyopa-
thy and diabetes), may aid in reducing cardiopulmonary
anesthetic risk and facilitate intubation (Fig. 1).
Case discussion
This is a case of acromegaly due to a giant, mixed GH- and
prolactin-secreting adenoma. In spite of cavernous sinus
invasion and optic chiasm compression, the patient did not
appear to have any significant mass effects from the tumor.
The patient had a striking response to pharmacological
treatment with combined SSA and dopamine agonist
therapy in terms of GH/IGF-1 and prolactin normalization,
as well as reduction in tumor volume. Upon presentation,
this patient had a minimal chance of surgical cure due to
supra and parasellar involvement (with cavernous sinus
invasion) of the pituitary macroadenoma, and thus repre-
sented a good candidate for primary pharmacological
therapy in line with current acromegaly treatment guide-
lines and consensus recommendations [3, 4, 6, 50]. Upon
long-term follow up, this young man was progressively
able to first discontinue the dopamine agonist and, later-on,
to reduce the dose of the SSA so after 3 years, he only
required 20 mg of octreotide LAR every 2 months to
maintain a GH of around 1 lg/L and an IGF-1 between 0.8
and 1.1 9 ULN. This patient’s increased responsiveness to
the SSA as time went by is a well-established observation
Case study: Successful primary pharmacological therapy for a tumor
with optic chiasm compression and limited chance of surgical cure
(Source: Ana Laura Espinosa de los Monteros, MD)
20 year old male
Progressive enlargement of hands and feet, as well as coarsening
of facial features since age 15
2 years prior to consultation he developed headaches, fatigue and
loud snoring
For the past 4 months he reports lack of morning erections and
decreased libido
No significant past medical history. He had progressed through
puberty unremarkably. No known allergies
Junior college student, actively engaged in sports. Does not
smoke; no history of substance abuse
Unremarkable family history
Physical examination
Pulse 67 bpm, BP 134/76 mmHg, Weight 103 kg, Height 1.83 m,
BMI 30 kg/m2
In no acute distress, evident acromegaloid features
Enlarged supracilliary arches, prognathism, macroglossia,
enlarged hands and feet
Oily and thick skin, skin tags over anterior chest; no
gynecomastia. Normal cardiopulmonary exam. No thyroid
enlargement, no palpable lymph nodes; no palpable spleen or
liver on abdominal examination. Gonadal exam appropriate for
age and gender
Normal visual fields by confrontation (confirmed by Goldmann
and automated perimetry), isochoric pupils, reacting normally to




GH nadir during OGTT = 5.3 lg/L (2-h glucose = 6.1 mmol/L
[110 mg/dL])
IGF-1: 1,110 lg/L (3.5 9 ULN)
Prolactin: 191 nmol/L (4,400 lg/L [normal 3–20 lg/L])
LH: 0.1 IU/L (normal 1.7–8.6 IU/L)
FSH: 0.3 IU/L (normal 1.5–12.4 IU/L)
Testosterone: 4.3 nmol/L (125 ng/dL [normal 280–800 ng/dL])
TSH: 0.3 mIU/L (normal 0.4–4.9 mIU/L)
Free T4: 5.1 pmol/L (0.4 ng/dL [normal 0.8–1.4 ng/dL])
Cortisol (8 AM): 254 nmol/L (9.2 lg/dL [normal 4.3–22.4 lg/
dL])
Pre-treatment MRI
Gadolinium-enhanced, T1-weighted MRI, coronal view (Fig. 1)
5.5 cm, hyperintense mass with a small cystic component
Left parasellar extension with cavernous sinus invasion
Suprasellar extension with optic chiasm compression
Treatment and course
SSA q. 4 weeks, cabergoline 1.5 mg q. week
Levothyroxine 100 lg QD, hydrocortisone 10 mg BID




IGF-1: 365 lg/L (1.15 9 ULN)
Prolactin: 304 pmol/L (7 lg/L)
LH: 0.5 IU/L; FSH: 1 IU/L; testosterone: 6.9 nmol/L (200 ng/dL)
Serum cortisol 83 nmol/L (3 lg/dL; after 5 days of withholding
hydrocortisone)
MRI after 6 months of treatment
Gadolinium-enhanced, T1-weighted MRI, coronal view (Fig. 1)
90 % reduction of tumor, herniation of optic chiasm,
aracnoidocele
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[13] and undoubtedly has an important economic impact
since the cost of therapy in the individual patient is sig-
nificantly lowered. Considering that the adenoma almost
disappeared with pharmacological therapy and the rela-
tively low doses of SSA required by the patient to achieve
biochemical control, we decided against submitting him to
secondary management with either surgery or radiation
therapy. Should this patient not have achieved biochemical
and tumoral remission with pharmacological management,
radiation therapy would have been an adequate option.
Both conformal external beam radiation therapy [52] and
radiosurgery [53] have proved to be effective and low-cost
alternatives and undoubtedly are useful tools in the multi-
modal strategy.
Unfortunately, presentation with large, often inoperable
tumors is encountered frequently in Latin America due to
delays in diagnosis and this can limit the options offered to
the patient, irrespective of the available resources [3].
Nevertheless, this case provides a good example of how
primary pharmacological therapy (in this instance using the
combination of an SSA and a dopamine agonist) can be
used to provide disease control in a patient with acro-
megaly who is initially not suitable for surgery. A major
drawback of SSA is the need for long-term, indefinite
therapy. In this regard, a substantial proportion of well-
controlled patients can progressively increase their injec-
tion interval and a small but non-negligible number can
eventually discontinue the drug [54].
Conclusions
Primary pharmacological therapy may be the only viable
option for many patients with acromegaly, especially those
presenting with advanced disease with large inoperable
tumors, as often occurs in Latin America [3]. In countries
with limited resources, primary pharmacological therapy
may also offer opportunities for disease control during
delays in referrals for surgery. Many patients on primary
pharmacological treatment will achieve good levels of
biochemical control over the long-term, as well as
decreased tumor size, improvements in symptoms and a
reduction in severity of comorbidities.
The current evidence suggests that only a quarter of
patients receiving SSA therapy for at least a year will not
achieve any significant improvement in GH and/or IGF-1
levels or a reduction in tumor size [15]. Although a SSA
is generally the drug of choice for first-line pharmaco-
therapy in acromegaly, in resource-poor regions, options
may often be limited to cheaper, less effective drug
classes. For instance, cabergoline may also be used as
primary pharmacological therapy, especially if access to
SSAs is limited.
Although access to SSAs has improved in Latin America,
the costs of pharmacological therapy remain an important
issue and it is worth considering opportunities for improving
the cost-effectiveness of SSA therapy 49]. For instance,
strategies that proactively utilize pharmacological therapies
in conjunction with surgery offer opportunities for improved
rates of biochemical control and cure [36, 49]. Furthermore,
the use of drug combination therapy and/or extended dosing
intervals may also help to improve response rates and reduce
SSA doses [49, 51]. Thus, although improved access to
recommended therapies would be the ideal solution, Latin
American clinicians may need a flexible approach in order
to maximize the benefits of primary pharmacological ther-
apy for acromegaly within their budget constraints and local
access to drug resources.
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